{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T18:28:53Z","timestamp":1784140133306,"version":"3.55.0"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T00:00:00Z","timestamp":1737936000000},"content-version":"vor","delay-in-days":26,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100001775","name":"University of Technology Sydney","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001775","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Drug Metab Pharmacokinet"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1007\/s13318-024-00928-x","type":"journal-article","created":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T20:01:50Z","timestamp":1738008110000},"page":"1-15","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["An Exploration of the Interplay Between Caffeine and Antidepressants Through the Lens of Pharmacokinetics and Pharmacodynamics"],"prefix":"10.1007","volume":"50","author":[{"given":"Jenny","family":"Truong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noor","family":"Abu-Suriya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Tory","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Bahho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Ismaiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thach","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Mansour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varsha","family":"Nand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julijana","family":"Saponja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamal","family":"Dua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7088-396X","authenticated-orcid":false,"given":"Gabriele","family":"De Rubis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Parisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,27]]},"reference":[{"key":"928_CR1","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.taap.2017.10.020","volume":"337","author":"A Szopa","year":"2017","unstructured":"Szopa A, Doboszewska U, Herbet M, Wo\u015bko S, Wyska E, \u015awi\u0105der K, Serefko A, Korga A, Wla\u017a A, Wr\u00f3bel A, Ostrowska M, Terlecka J, Kanadys A, Poleszak E, Dudka J, Wla\u017a P. Chronic treatment with caffeine and its withdrawal modify the antidepressant-like activity of selective serotonin reuptake inhibitors in the forced swim and tail suspension tests in mice. Effects on Comt, Slc6a15 and Adora1 gene expression. J Toxicol Appl Pharmacol. 2017;337:95\u2013103. https:\/\/doi.org\/10.1016\/j.taap.2017.10.020.","journal-title":"J Toxicol Appl Pharmacol."},{"key":"928_CR2","unstructured":"AMH. Australian Medicines Handbook. ASCEPT, PSA & the RACGP. 2023."},{"issue":"3","key":"928_CR3","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1177\/009127009903900308","volume":"39","author":"J Amchin","year":"1999","unstructured":"Amchin J, Zarycranski W, Taylor KP, Albano D, Klockowski PM. Effect of venlafaxine on CYP1A2-dependent pharmacokinetics and metabolism of caffeine. J Clin Pharmacol. 1999;39(3):252\u20139. https:\/\/doi.org\/10.1177\/009127009903900308.","journal-title":"J Clin Pharmacol"},{"key":"928_CR4","unstructured":"World Health Organization (WHO). Mental disorders. 2022. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/mental-disorders"},{"issue":"3","key":"928_CR5","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/S0090-9556(25)07190-9","volume":"19","author":"F Berthou","year":"1991","unstructured":"Berthou F, Flinois JP, Ratanasavanh D, Beaune P, Riche C, Guillouzo A. Evidence for the involvement of several cytochromes P-450 in the first steps of caffeine metabolism by human liver microsomes. Drug Metab Dispos. 1991;19(3):561\u20137.","journal-title":"Drug Metab Dispos"},{"issue":"9","key":"928_CR6","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1111\/jphp.12954","volume":"70","author":"K Bogatko","year":"2018","unstructured":"Bogatko K, Poleszak E, Szopa A, Wyska E, Wla\u017a P, \u015awi\u0105der K, Wla\u017a A, Doboszewska U, Rojek K, Serefko A. The influence of selective A1 and A2A receptor antagonists on the antidepressant-like activity of moclobemide, venlafaxine and bupropion in mice. J Pharm Pharmacol. 2018;70(9):1200\u20138. https:\/\/doi.org\/10.1111\/jphp.12954.","journal-title":"J Pharm Pharmacol"},{"issue":"3","key":"928_CR7","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1034\/j.1600-0773.2002.900306.x","volume":"90","author":"L Brachtendorf","year":"2002","unstructured":"Brachtendorf L, Jetter A, Beckurts KT, H\u00f6lscher AH, Fuhr U. Cytochrome P450 enzymes contributing to demethylation of maprotiline in man. Pharmacol Toxicol. 2002;90(3):144\u20139. https:\/\/doi.org\/10.1034\/j.1600-0773.2002.900306.x.","journal-title":"Pharmacol Toxicol"},{"key":"928_CR8","unstructured":"Broderick PJ, Benjamin AB, Dennis LW. Caffeine and psychiatric medication interactions: a review. J Okla State Med Assoc. 2005;98(8):380\u20134. https:\/\/pubmed.ncbi.nlm.nih.gov\/16206866\/"},{"issue":"6","key":"928_CR9","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1517\/17425255.2014.907794","volume":"10","author":"M Buoli","year":"2014","unstructured":"Buoli M, Mauri MC, Altamura AC. Pharmacokinetic evaluation of agomelatine for the treatment of generalised anxiety disorder. Expert Opin Drug Metab Toxicol. 2014;10(6):885\u201392. https:\/\/doi.org\/10.1517\/17425255.2014.907794.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"928_CR10","doi-asserted-by":"publisher","unstructured":"Buysse DJ, Schweitzer PK, Moul DE. Chapter 37 - Clinical pharmacology of other drugs used as hypnotics. Princ and Prac of Sleep Med. 5th ed. 2011; pp. 452\u201367. https:\/\/doi.org\/10.1016\/B0-72-160797-7\/50044-6","DOI":"10.1016\/B0-72-160797-7\/50044-6"},{"issue":"2","key":"928_CR11","doi-asserted-by":"publisher","first-page":"127","DOI":"10.2165\/00003088-200039020-00004","volume":"39","author":"JA Carrillo","year":"2000","unstructured":"Carrillo JA, Benitez J. Clinically significant pharmacokinetic interactions between dietary caffeine and medications. Clin Pharmacokinet. 2000;39(2):127\u201353. https:\/\/doi.org\/10.2165\/00003088-200039020-00004.","journal-title":"Clin Pharmacokinet"},{"issue":"10","key":"928_CR12","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1007\/s40261-013-0117-6","volume":"33","author":"G Chen","year":"2013","unstructured":"Chen G, Lee R, H\u00f8jer A-M, Buchbjerg JK, Serenko M, Zhao Z. Pharmacokinetic drug interactions involving vortioxetine (Lu AA21004), a multimodal antidepressant. Clin Drug Investig. 2013;33(10):727\u201336. https:\/\/doi.org\/10.1007\/s40261-013-0117-6.","journal-title":"Clin Drug Investig"},{"issue":"6","key":"928_CR13","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1007\/s40262-017-0612-7","volume":"57","author":"G Chen","year":"2017","unstructured":"Chen G, Lee R, H\u00f8jer A-M, Buchbjerg JK, Areberg J, Nomikos G. Vortioxetine: clinical pharmacokinetics and drug interactions. Clin Pharmacokinet. 2017;57(6):673\u201386. https:\/\/doi.org\/10.1007\/s40262-017-0612-7.","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"928_CR14","first-page":"529","volume":"24","author":"L Chen","year":"1996","unstructured":"Chen L, Bondoc FY, Lee MJ, Russin AHJ, Thomas PE, Yang CS. Caffeine induces cytochrome P4501A2 induction of CYP1A2 by tea in rats. Drug Metab Dispos. 1996;24(5):529\u201333.","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"928_CR15","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1067\/mcp.2002.121788","volume":"71","author":"M Christensen","year":"2002","unstructured":"Christensen M, Tybring G, Mihara K, Yasui-Furokori N, Carrillo JA, Ramos SI, Andersson K, Dahl ML, Bertilsson L. Low daily 10-mg and 20-mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19). Clin Pharmacol Ther. 2002;71(3):141\u201352. https:\/\/doi.org\/10.1067\/mcp.2002.121788.","journal-title":"Clin Pharmacol Ther"},{"key":"928_CR16","unstructured":"Chu A, Wadhwa R. Selective Serotonin Reuptake Inhibitors. [Updated 2023 May 1]. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK554406\/. Accessed 24 Oct 2024."},{"issue":"5","key":"928_CR17","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1111\/j.1365-2125.2005.02467.x","volume":"60","author":"KE Culm-Merdek","year":"2005","unstructured":"Culm-Merdek KE, von Moltke LL, Harmatz JS, Greenblatt DJ. Fluvoxamine impairs single-dose caffeine clearance without altering caffeine pharmacodynamics. Br J Clin Pharmacol. 2005;60(5):486\u201393. https:\/\/doi.org\/10.1111\/j.1365-2125.2005.02467.x.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"928_CR18","first-page":"36","volume":"40","author":"A D'Agostino","year":"2015","unstructured":"D\u2019Agostino A, English CD, Rey JA. Vortioxetine (Brintellix): a new serotonergic antidepressant. P&T. 2015;40(1):36\u201340.","journal-title":"P&T"},{"issue":"6","key":"928_CR19","first-page":"1045","volume":"55","author":"WA Daniel","year":"2003","unstructured":"Daniel WA, Kot M, W\u00f3jcikowski J. Effects of classic and newer antidepressants on the oxidation pathways of caffeine in rat liver. In vitro study Pol J Pharmacol. 2003;55(6):1045\u201353.","journal-title":"In vitro study. Pol J Pharmacol."},{"key":"928_CR20","unstructured":"De Boer T. The pharmacologic profile of mirtazapine. J Clin Psychiatry. 1996; 57(4): 19\u201325. https:\/\/pubmed.ncbi.nlm.nih.gov\/8636062\/"},{"issue":"1","key":"928_CR21","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/S0090-9556(25)06042-8","volume":"9","author":"GD De Jongh","year":"1981","unstructured":"De Jongh GD, Van Den Wildenberg HM, Nieuwenhuyse H, Van Der Veen F. The metabolism of mianserin in women, rabbits, and rats. Identification of the major urinary metabolites. Drug Metab Dispos. 1981;9(1):48\u201353.","journal-title":"Drug Metab Dispos"},{"key":"928_CR22","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-062197","author":"C Lunghi","year":"2022","unstructured":"Lunghi C, Dugas M, Leclerc J, Poluzzi E, Martineau C, Carnovale V, St\u00e9fan T, Blouin P, L\u00e9pine J, Jalbert L, Espinoza Suarez NR, Svyntozelska O, Dery M-P, Ekanmian G, Nogueira DM, Akinola PS, Turcotte S, Skidmore B, Leblanc A. Global prevalence of antidepressant drug utilization in the community: protocol for a systematic review. BMJ Open. 2022. https:\/\/doi.org\/10.1136\/bmjopen-2022-062197.","journal-title":"BMJ Open"},{"issue":"9","key":"928_CR23","first-page":"632","volume":"65","author":"V DeLucia","year":"2016","unstructured":"DeLucia V, Kelsberg G, Safranek S. Which SSRIs most effectively treat depression in adolescents? J Fam Pract. 2016;65(9):632\u20134.","journal-title":"J Fam Pract"},{"issue":"4","key":"928_CR24","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s00228-007-0438-6","volume":"64","author":"N Djordjevic","year":"2008","unstructured":"Djordjevic N, Ghotbi R, Bertilsson L, Jankovic S, Aklillu E. Induction of CYP1A2 by heavy coffee consumption in Serbs and Swedes. Eur J Clin Pharmacol. 2008;64(4):381\u20135. https:\/\/doi.org\/10.1007\/s00228-007-0438-6.","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"928_CR25","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/S0924-977X(97)00417-3","volume":"7","author":"P Dostert","year":"1997","unstructured":"Dostert P, Benedetti MS, Poggesi I. Review of the pharmacokinetic and metabolism of reboxetine, a selective noradrenaline reuptake inhibitor. Eur Neuropsychopharmacol. 1997;7(1):23\u201335. https:\/\/doi.org\/10.1016\/S0924-977X(97)00417-3.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"2\u20133","key":"928_CR26","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/s0014-2999(00)00336-8","volume":"399","author":"MJ Esser","year":"2000","unstructured":"Esser MJ, Sawynok J. Caffeine blockade of the thermal antihyperalgesic effect of acute amitriptyline in a rat model of neuropathic pain. Eur J Pharmacol. 2000;399(2\u20133):131\u20139. https:\/\/doi.org\/10.1016\/s0014-2999(00)00336-8.","journal-title":"Eur J Pharmacol"},{"key":"928_CR27","unstructured":"Evans J, Richards J, Battisti AS. Caffeine. [Updated 2024 May 29]. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2024. Available From: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK519490\/. Accessed 31 Oct 2024."},{"issue":"4","key":"928_CR28","doi-asserted-by":"publisher","first-page":"497","DOI":"10.3390\/neurolint13040049","volume":"13","author":"D Fanelli","year":"2021","unstructured":"Fanelli D, Weller G, Liu H. New serotonin-norepinephrine reuptake inhibitors and their anesthetic and analgesic considerations. Neurol Int. 2021;13(4):497\u2013509. https:\/\/doi.org\/10.3390\/neurolint13040049.","journal-title":"Neurol Int"},{"issue":"2","key":"928_CR29","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/0304-3940(96)12577-5","volume":"208","author":"S Ferre","year":"1996","unstructured":"Ferre S, Popoli P, Tinner-Staines B, Fuxe K. Adenosine A1 receptor-dopamine D1 receptor interaction in the rat limbic system: modulation of dopamine D1 receptor antagonist binding sites. Neurosci Lett. 1996;208(2):109\u201312. https:\/\/doi.org\/10.1016\/0304-3940(96)12577-5.","journal-title":"Neurosci Lett"},{"issue":"7\u20138","key":"928_CR30","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1007\/s00018-003-3269-3","volume":"61","author":"G Fisone","year":"2004","unstructured":"Fisone G, Borgkvist A, Usiello A. Caffeine as a psychomotor stimulant: mechanism of action. Cell Mol Life Sci. 2004;61(7\u20138):857\u201372. https:\/\/doi.org\/10.1007\/s00018-003-3269-3.","journal-title":"Cell Mol Life Sci"},{"issue":"5","key":"928_CR31","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1017\/S1092852916000651","volume":"22","author":"K Gillman","year":"2017","unstructured":"Gillman K. \u201cMuch ado about nothing\u201d: monoamine oxidase inhibitors, drug interactions, and dietary tyramine. CNS Spectr. 2017;22(5):385\u20137. https:\/\/doi.org\/10.1017\/S1092852916000651.","journal-title":"CNS Spectr"},{"issue":"1","key":"928_CR32","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1097\/JCP.0b013e31820469ea","volume":"31","author":"PK Gillman","year":"2011","unstructured":"Gillman PK. Advances pertaining to the pharmacology and interactions of irreversible nonselective monoamine oxidase inhibitors. J Clin Psychopharmacol. 2011;31(1):66\u201374. https:\/\/doi.org\/10.1097\/JCP.0b013e31820469ea.","journal-title":"J Clin Psychopharmacol"},{"key":"928_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.752826","volume":"12","author":"J Grzegorzewski","year":"2022","unstructured":"Grzegorzewski J, Bartsch F, K\u00f6ller A, K\u00f6nig M. Pharmacokinetics of caffeine: a systematic analysis of reported data for application in metabolic phenotyping and liver function testing. Front Pharmacol. 2022;12: 752826. https:\/\/doi.org\/10.3389\/fphar.2021.752826.","journal-title":"Front Pharmacol"},{"issue":"8","key":"928_CR34","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.lfs.2005.05.074","volume":"78","author":"T Herraiz","year":"2006","unstructured":"Herraiz T, Chaparro C. Human monoamine oxidase enzyme inhibition by coffee and \u03b2-carbolines norharman and harman isolated from coffee. Life Sci. 2006;78(8):795\u2013802. https:\/\/doi.org\/10.1016\/j.lfs.2005.05.074.","journal-title":"Life Sci"},{"issue":"14","key":"928_CR35","doi-asserted-by":"publisher","first-page":"2609","DOI":"10.1007\/s00213-015-3898-x","volume":"232","author":"K Hodgson","year":"2015","unstructured":"Hodgson K, Tansey KE, Uher R, Dernov\u0161ek MZ, Mors O, Hauser J, Souery D, Maier W, Henigsberg N, Rietschel M, Placentino A, Craig IW, Aitchison KJ, Farmer AE, Dobson RJB, McGuffin P. Exploring the role of drug-metabolising enzymes in antidepressant side effects. Psychopharmacology. 2015;232(14):2609\u201317. https:\/\/doi.org\/10.1007\/s00213-015-3898-x.","journal-title":"Psychopharmacology"},{"key":"928_CR36","unstructured":"Human Metabolome Database. Tranylcypromine. 2022. https:\/\/hmdb.ca\/metabolites\/HMDB0014890. Accessed 31 Sep 2023."},{"key":"928_CR37","unstructured":"Institute for Quality and Efficiency in Health Care (IQWiG). Depression: How effective are antidepressants? IQWIG. 2006. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK361016\/#:~:text=Studies%20show%20that%20the%20benefit. Accessed 2 Oct 2023."},{"key":"928_CR38","unstructured":"Institute of Medicine (US) Committee on Military Nutrition Research. Caffeine for the Sustainment of Mental Task Performance: Formulations for Military Operations. Washington (DC): National Academies Press (US); 2001. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK223808\/. Accessed 2 Oct 2023."},{"key":"928_CR39","doi-asserted-by":"publisher","DOI":"10.1152\/ajpregu.00114.2014","author":"J John","year":"2014","unstructured":"John J, Kodama T, Siegel JM. Caffeine promotes glutamate and histamine release in the posterior hypothalamus. Am J Physiol Regul Integr Comp Physiol. 2014. https:\/\/doi.org\/10.1152\/ajpregu.00114.2014.","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"928_CR40","unstructured":"Kot M, Daniel W. Caffeine as a marker substrate for testing cytochrome P450 activity in human and rat. Pol J Pharmacol. 2008; 60:389\u201397. http:\/\/if-pan.krakow.pl\/pjp\/pdf\/2008\/6_789.pdf"},{"key":"928_CR41","doi-asserted-by":"publisher","first-page":"145","DOI":"10.2165\/00023210-199503020-00006","volume":"3","author":"G Laux","year":"1995","unstructured":"Laux G, Volz H, M\u00f6ller H. Newer and older monoamine oxidase inhibitors. CNS Drugs. 1995;3:145\u201358. https:\/\/doi.org\/10.2165\/00023210-199503020-00006.","journal-title":"CNS Drugs"},{"key":"928_CR42","doi-asserted-by":"crossref","unstructured":"Lemoine A, Gautier JC, Azoulay D, Kiffel L, Belloc C, Guengerich FP, Maurel P, Beaune P, Leroux JP. Major pathway of imipramine metabolism is catalyzed by cytochromes P-450 1A2 and P-450 3A4 in human liver. Mol Pharmacol. 1993;43(5):827\u201332. https:\/\/pubmed.ncbi.nlm.nih.gov\/8502233\/","DOI":"10.1016\/S0026-895X(25)13662-6"},{"key":"928_CR43","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-062197","author":"C Lunghi","year":"2022","unstructured":"Lunghi C, Dugas M, Leclerc J, Poluzzi E, Martineau C, Carnovale V, St\u00e9fan T, Blouin P, L\u00e9pine J, Jalbert L, Suarez NRE, Svyntozelska O, Dery M-P, Ekanmian G, Nogueira DM, Akinola PS, Turcotte S, Skidmore B, Leblanc A. Global prevalence of antidepressant drug utilization in the community: protocol for a systematic review. BMJ Open. 2022. https:\/\/doi.org\/10.1136\/bmjopen-2022-062197.","journal-title":"BMJ Open"},{"issue":"1","key":"928_CR44","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/BF00558388","volume":"19","author":"K Lynn","year":"1981","unstructured":"Lynn K, Braithwaite R, Dawling S, Rosser R. Comparison of the serum protein binding of maprotiline and phenytoin in uraemic patients on haemodialysis. Eur J Clin Pharmacol. 1981;19(1):73\u20137. https:\/\/doi.org\/10.1007\/BF00558388.","journal-title":"Eur J Clin Pharmacol"},{"key":"928_CR45","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.3389\/fgene.2019.01199","volume":"10","author":"S Maggo","year":"2019","unstructured":"Maggo S, Kennedy MA, Barczyk ZA, Miller AL, Rucklidge JJ, Mulder RT, Foulds JA. Common CYP2D6, CYP2C9, and CYP2C19 gene variants, health anxiety, and neuroticism are not associated with self-reported antidepressant side effects. Front Genet. 2019;10:1199. https:\/\/doi.org\/10.3389\/fgene.2019.01199.","journal-title":"Front Genet"},{"key":"928_CR46","unstructured":"Moraczewski J, Awosika AO, Aedma KK. Tricyclic antidepressants. [Updated 2023 August 17]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK557791\/#:~:text=Tricyclic%20antidepressants%20(TCAs)%20constitute%20a,attention%2C%20and%20pain%20in%20individuals. Accessed 31 October 2024."},{"key":"928_CR47","unstructured":"National Library of Medicine. Phenelzine. Pubchem. 2023. https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Phenelzine"},{"key":"928_CR48","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1111\/j.1600-0447.1981.tb00731.x","volume":"63","author":"SO \u00d6Gren","year":"1981","unstructured":"\u00d6Gren SO, Cott JM, Hall H. Sedative\/anxiolytic effects of antidepressants in animals. Acta Psychiatr Scand. 1981;63:277\u201388. https:\/\/doi.org\/10.1111\/j.1600-0447.1981.tb00731.x.","journal-title":"Acta Psychiatr Scand"},{"issue":"7","key":"928_CR49","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1093\/sleep\/33.7.930","volume":"33","author":"M Okuro","year":"2010","unstructured":"Okuro M, Fujiki N, Kotorii N, Ishimaru Y, Sokoloff P, Nishino S. Effects of paraxanthine and caffeine on sleep, locomotor activity, and body temperature in orexin\/ataxin-3 transgenic narcoleptic mice. Sleep. 2010;33(7):930\u201342. https:\/\/doi.org\/10.1093\/sleep\/33.7.930.","journal-title":"Sleep"},{"key":"928_CR50","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/j.neuropharm.2012.11.029","volume":"67","author":"M Orr\u00fa","year":"2013","unstructured":"Orr\u00fa M, Guitart X, Karcz-Kubicha M, Solinas M, Justinova Z, Barodia SK, Zanoveli J, Cortes A, Lluis C, Casado V, Moeller FG, Ferr\u00e9 S. Psychostimulant pharmacological profile of paraxanthine, the main metabolite of caffeine in humans. Neuropharmacology. 2013;67:476\u201384. https:\/\/doi.org\/10.1016\/j.neuropharm.2012.11.029.","journal-title":"Neuropharmacology"},{"issue":"4","key":"928_CR51","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1111\/j.1527-3458.2003.tb00258.x","volume":"9","author":"ME Page","year":"2003","unstructured":"Page ME. The promises and pitfalls of reboxetine. CNS Drug Rev. 2003;9(4):327\u201342. https:\/\/doi.org\/10.1111\/j.1527-3458.2003.tb00258.x.","journal-title":"CNS Drug Rev"},{"key":"928_CR52","unstructured":"Parikh N, Yilanli M, Saadabadi A. Tranylcypromine. [Updated 2023 July 14]. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2024. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK459162\/. Accessed 31 Oct 2024."},{"issue":"7","key":"928_CR53","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.lfs.2013.06.020","volume":"93","author":"A Petzer","year":"2013","unstructured":"Petzer A, Pienaar A, Petzer JP. The interactions of caffeine with monoamine oxidase. Life Sci. 2013;93(7):283\u20137. https:\/\/doi.org\/10.1016\/j.lfs.2013.06.020.","journal-title":"Life Sci"},{"issue":"1","key":"928_CR54","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.pharep.2015.06.138","volume":"68","author":"E Poleszak","year":"2016","unstructured":"Poleszak E, Szopa A, Wyska E, Kuku\u0142a-Koch W, Serefko A, Wo\u015bko S, Wla\u017a P. Caffeine augments the antidepressant-like activity of mianserin and agomelatine in forced swim and tail suspension tests in mice. Pharmacol Rep. 2016;68(1):56\u201361. https:\/\/doi.org\/10.1016\/j.pharep.2015.06.138.","journal-title":"Pharmacol Rep"},{"key":"928_CR55","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.lfs.2015.06.008","volume":"136","author":"E Poleszak","year":"2015","unstructured":"Poleszak E, Szopa A, Wyska E, Wo\u015bko S, Serefko A, Wla\u017a P, Pier\u00f3g M, Wr\u00f3bel A, Wla\u017a P. The influence of caffeine on the activity of moclobemide, venlafaxine, bupropion and milnacipran in the forced swim test in mice. Life Sci. 2015;136:13\u20138. https:\/\/doi.org\/10.1016\/j.lfs.2015.06.008.","journal-title":"Life Sci"},{"key":"928_CR56","unstructured":"Sabri MA, Saber-Ayad MM. MAO inhibitors. [Updated 2023 June 5]. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2024. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK557395\/. Accessed 24 Oct 2024."},{"issue":"2","key":"928_CR57","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s00213-013-3146-1","volume":"230","author":"H Sato","year":"2013","unstructured":"Sato H, Ito C, Tashiro M, Hiraoka K, Shibuya K, Funaki Y, Yanai K. Histamine H1 receptor occupancy by the new-generation antidepressants fluvoxamine and mirtazapine: a positron emission tomography study in healthy volunteers. Psychopharmacology. 2013;230(2):227\u201334. https:\/\/doi.org\/10.1007\/s00213-013-3146-1.","journal-title":"Psychopharmacology"},{"issue":"2","key":"928_CR58","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.neulet.2008.05.074","volume":"440","author":"J Sawynok","year":"2008","unstructured":"Sawynok J, Reid A, Fredholm BB. Caffeine reverses antinociception by amitriptyline in wild type mice but not in those lacking adenosine A1 receptors. Neurosci Lett. 2008;440(2):181\u20134. https:\/\/doi.org\/10.1016\/j.neulet.2008.05.074.","journal-title":"Neurosci Lett"},{"key":"928_CR59","unstructured":"Sheffler ZM, Patel P, Abdijadid S. Antidepressants. [Updated 2023 May 26]. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2024. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK538182\/. Accessed 31 Oct 2024."},{"issue":"9","key":"928_CR60","doi-asserted-by":"publisher","first-page":"10783","DOI":"10.3390\/ijerph120910783","volume":"12","author":"G Shen","year":"2015","unstructured":"Shen G, Wang C, Zhou L, Li L, Chen H, Yu W, Li H. CYP450 enzyme-mediated metabolism of TCAs and its inhibitory and induced effects on metabolized enzymes in vitro. Int J Environ Res Public Health. 2015;12(9):10783\u201393. https:\/\/doi.org\/10.3390\/ijerph120910783.","journal-title":"Int J Environ Res Public Health"},{"key":"928_CR61","unstructured":"Sidhu G, Marwaha R. Phenelzine. [Updated 2023 March 6]. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2024. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK554508\/ Accessed 31 Oct 2024."},{"key":"928_CR62","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2019.172732","volume":"865","author":"SS Sk\u00e5nland","year":"2019","unstructured":"Sk\u00e5nland SS, Cie\u015blar-Pobuda A. Off-label uses of drugs for depression. Eur J Pharmacol. 2019;865: 172732. https:\/\/doi.org\/10.1016\/j.ejphar.2019.172732.","journal-title":"Eur J Pharmacol"},{"key":"928_CR63","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/s002280050531","volume":"54","author":"O Sprigset","year":"1998","unstructured":"Sprigset O. Are adverse drug reactions attributed to fluvoxamine caused by concomitant intake of caffeine? Eur J Clin Pharmacol. 1998;54:665\u20136. https:\/\/doi.org\/10.1007\/s002280050531.","journal-title":"Eur J Clin Pharmacol"},{"issue":"7","key":"928_CR64","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1016\/S0149-2918(08)80047-1","volume":"30","author":"E Spina","year":"2008","unstructured":"Spina E, Santoro V, D\u2019Arrigo C. Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update. Drug Saf. 2008;30(7):1206\u201327. https:\/\/doi.org\/10.1016\/S0149-2918(08)80047-1.","journal-title":"Drug Saf"},{"key":"928_CR65","unstructured":"Sub Laban T, Saadabadi A. Monoamine oxidase inhibitors (MAOI). [Updated 2023 July 17]. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2024. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK539848\/ . Accessed 31 Oct 2024."},{"issue":"12","key":"928_CR66","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1007\/s00210-018-1551-z","volume":"391","author":"A Szopa","year":"2018","unstructured":"Szopa A, Poleszak E, Bogatko K, Wyska E, Wo\u015bko S, Doboszewska U, \u015awi\u0105der K, Wla\u017a A, Dudka J, Wr\u00f3bel A, Wla\u017a P, Serefko A. DPCPX, a selective adenosine A1 receptor antagonist, enhances the antidepressant-like effects of imipramine, escitalopram, and reboxetine in mice behavioral tests. Naunyn Schmiedebergs Arch Pharmacol. 2018;391(12):1361\u201371. https:\/\/doi.org\/10.1007\/s00210-018-1551-z.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"2","key":"928_CR67","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s00210-015-1189-z","volume":"389","author":"A Szopa","year":"2016","unstructured":"Szopa A, Poleszak E, Wyska E, Serefko A, Wo\u015bko S, Wla\u017a A, Pier\u00f3g M, Wr\u00f3bel A, Wla\u017a P. Caffeine enhances the antidepressant-like activity of common antidepressant drugs in the forced swim test in mice. Naunyn Schmiedebergs Arch Pharmacol. 2016;389(2):211\u201321. https:\/\/doi.org\/10.1007\/s00210-015-1189-z.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"6","key":"928_CR68","doi-asserted-by":"publisher","first-page":"461","DOI":"10.2165\/00003088-200038060-00001","volume":"38","author":"CJ Timmer","year":"2000","unstructured":"Timmer CJ, Sitsen JM, Delbressine LP. Clinical pharmacokinetics of mirtazapine. Clin Pharmacokinet. 2000;38(6):461\u201374. https:\/\/doi.org\/10.2165\/00003088-200038060-00001.","journal-title":"Clin Pharmacokinet"},{"issue":"8","key":"928_CR69","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.euroneuro.2017.05.007","volume":"27","author":"S Ulrich","year":"2017","unstructured":"Ulrich S, Ricken R, Adli M. Tranylcypromine in mind (Part I): review of pharmacology. Eur Neuropsychopharmacol. 2017;27(8):697\u2013713. https:\/\/doi.org\/10.1016\/j.euroneuro.2017.05.007.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"2","key":"928_CR70","doi-asserted-by":"publisher","first-page":"116","DOI":"10.2174\/187231212804096745","volume":"6","author":"D Vaynshteyn","year":"2012","unstructured":"Vaynshteyn D, Jeong H. Caffeine induces CYP1A2 expression in rat hepatocytes but not in human hepatocytes. Drug Metab Lett. 2012;6(2):116\u20139. https:\/\/doi.org\/10.2174\/187231212804096745.","journal-title":"Drug Metab Lett"},{"issue":"1","key":"928_CR71","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/S0161-813X(03)00097-4","volume":"25","author":"M Yamada","year":"2004","unstructured":"Yamada M, Yasuhara H. Clinical pharmacology of MAO inhibitors: safety and future. Neurotoxicology. 2004;25(1):215\u201321. https:\/\/doi.org\/10.1016\/S0161-813X(03)00097-4.","journal-title":"Neurotoxicology"},{"issue":"6","key":"928_CR72","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.jsams.2014.07.017","volume":"18","author":"Y Zhang","year":"2015","unstructured":"Zhang Y, Coca A, Casa DJ, Antonio J, Green JM, Bishop PA. Caffeine and diuresis during rest and exercise: a meta-analysis. J Sci Med Sport. 2015;18(6):569\u201374. https:\/\/doi.org\/10.1016\/j.jsams.2014.07.017.","journal-title":"J Sci Med Sport"},{"issue":"5","key":"928_CR73","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1097\/FPC.0b013e3283505d5e","volume":"22","author":"CF Thorn","year":"2012","unstructured":"Thorn CF, Aklillu E, McDonagh EM, Klein TE, Altman RB. PharmGKB summary: caffeine pathway. Pharmacogenet Genomics. 2012;22(5):389\u201395. https:\/\/doi.org\/10.1097\/FPC.0b013e3283505d5e.","journal-title":"Pharmacogenet Genomics"},{"key":"928_CR74","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2021\/6699028","volume":"2021","author":"NR Marasine","year":"2021","unstructured":"Marasine NR, Sankhi S, Lamichhane R, Marasini NR, Dangi NB. Use of antidepressants among patients diagnosed with depression: a scoping review. Biomed Res Int. 2021;2021:1\u20138. https:\/\/doi.org\/10.1155\/2021\/6699028.","journal-title":"Biomed Res Int"}],"container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-024-00928-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13318-024-00928-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-024-00928-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T06:49:03Z","timestamp":1738824543000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13318-024-00928-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":74,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["928"],"URL":"https:\/\/doi.org\/10.1007\/s13318-024-00928-x","relation":{},"ISSN":["0378-7966","2107-0180"],"issn-type":[{"value":"0378-7966","type":"print"},{"value":"2107-0180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"5 November 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no conflicts of interest to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All the authors consent to publish the present paper.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"JT, NAS, DT, RB, AI, TN, AM, VN, JS: Conceptualization, Writing-Original Draft, Writing - Review and Editing; KD, GDR, DP: Conceptualization, Supervision, Project Administration, Writing - Review and Editing.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}